Trial Profile
A retrospective study evaluating reasons of lenalidomide discontinuation in patients with relapsed or refractory multiple myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jan 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 19 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology